German science and technology group Merck is open to more acquisitions for its Life Science business after announcing in May ...

Germany-based Merck KGaA has announced the launch of a new €290m ($317.6m) biosafety testing facility in Rockville, Maryland, ...

Merck is immune from an antitrust lawsuit accusing it of misleading regulators about the effectiveness of its mumps vaccine ...

German science and technology giant Merck on Thursday said it is confident of returning to medium-term growth after a ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Boston has become world-famous for its booming biotech industry. Over the past 20 years, the city has been buzzing with ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...

Merck & Co. has picked up options on two Evaxion Biotech vaccine candidates, paying $3.2 million and dangling more than $1 billion in milestones for the chance to pick up preclinical prospects ...

Merck's Keytruda could face competition from a newer medicine. The company's crown jewel will also lose patent exclusivity in a few years. Merck should have the means to get around these headwinds ...

Less attention has been paid to Akeso, a Chinese biotech that had kept a low profile until its drug bested Merck’s mega-blockbuster Keytruda in a late-stage lung cancer trial. Now, Akeso’s ...

Merck (MRK) closed the latest trading day at $113.09, indicating a -1.43% change from the previous session's end. This change lagged the S&P 500's daily gain of 0.4%. Elsewhere, the Dow gained 0. ...